Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005
- PMID: 19224838
- PMCID: PMC2668555
- DOI: 10.1200/JCO.2008.20.7753
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005
Abstract
Purpose: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Incidence rates are increasing in the United States. Monitoring incidence, survival, and mortality rates within at-risk populations can facilitate control efforts.
Methods: Age-adjusted incidence trends for HCC were examined in the Surveillance, Epidemiology, and End Results (SEER) registries from 1975 to 2005. Age-specific rates were examined for birth cohorts born between 1900 and 1959. Age-adjusted incidence and cause-specific survival rates from 1992 to 2005 were examined in the SEER 13 registries by race/ethnicity, stage, and treatment. United States liver cancer mortality rates were also examined.
Results: Age-adjusted HCC incidence rates tripled between 1975 and 2005. Incidence rates increased in each 10-year birth cohort from 1900 through the 1950s. Asians/Pacific Islanders had higher incidence and mortality rates than other racial/ethnic groups, but experienced a significant decrease in mortality rates over time. From 2000 to 2005, marked increases in incidence rates occurred among Hispanic, black, and white middle-aged men. Between 1992 and 2004, 2- to 4-year HCC survival rates doubled, as more patients were diagnosed with localized and regional HCC and prognosis improved, particularly for patients with reported treatment. Recent 1-year survival rates remained, however, less than 50%.
Conclusion: HCC incidence and mortality rates continue to increase, particularly among middle-aged black, Hispanic, and white men. Screening of at-risk groups and treatment of localized-stage tumors may contribute to increasing HCC survival rates in the United States. More progress is needed.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Similar articles
-
Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.Am J Gastroenterol. 2014 Apr;109(4):542-53. doi: 10.1038/ajg.2014.11. Epub 2014 Feb 11. Am J Gastroenterol. 2014. PMID: 24513805 Free PMC article.
-
Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States.Clin Gastroenterol Hepatol. 2020 Jan;18(1):242-248.e5. doi: 10.1016/j.cgh.2019.04.043. Epub 2019 Apr 28. Clin Gastroenterol Hepatol. 2020. PMID: 31042582 Free PMC article.
-
Epidemiology of hepatocellular carcinoma in Hispanics in the United States.Arch Intern Med. 2007 Oct 8;167(18):1983-9. doi: 10.1001/archinte.167.18.1983. Arch Intern Med. 2007. PMID: 17923599
-
Hepatocellular carcinoma: recent trends in the United States.Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34. doi: 10.1053/j.gastro.2004.09.013. Gastroenterology. 2004. PMID: 15508094 Review.
-
Hepatocellular carcinoma: an epidemiologic view.J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8. doi: 10.1097/00004836-200211002-00002. J Clin Gastroenterol. 2002. PMID: 12394209 Review.
Cited by
-
Construction of a prognostic model based on nine immune-related genes and identification of small molecule drugs for hepatocellular carcinoma (HCC).Am J Transl Res. 2020 Sep 15;12(9):5108-5130. eCollection 2020. Am J Transl Res. 2020. PMID: 33042409 Free PMC article.
-
GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay.Biochem Biophys Rep. 2022 Aug 13;31:101324. doi: 10.1016/j.bbrep.2022.101324. eCollection 2022 Sep. Biochem Biophys Rep. 2022. PMID: 36032401 Free PMC article.
-
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.World J Hepatol. 2015 May 28;7(9):1157-67. doi: 10.4254/wjh.v7.i9.1157. World J Hepatol. 2015. PMID: 26019732 Free PMC article. Review.
-
Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma.World J Gastroenterol. 2022 Aug 7;28(29):3793-3802. doi: 10.3748/wjg.v28.i29.3793. World J Gastroenterol. 2022. PMID: 36157533 Free PMC article. Review.
-
Extrahepatic metastases as initial manifestations of hepatocellular carcinoma: an Egyptian experience.Diagn Pathol. 2015 Jun 30;10:82. doi: 10.1186/s13000-015-0313-1. Diagn Pathol. 2015. PMID: 26122043 Free PMC article.
References
-
- Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer. 2001;94:153–156. - PubMed
-
- Curado MP, Edwards B, Shin HR, et al., editors. Vol. IX. Lyon, France: IARC; 2007. Cancer Incidence in Five Continents. IARC Scientific Publications, No. 160.
-
- El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med. 2003;139:817–823. - PubMed
-
- Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110:2119–2152. - PubMed
-
- Ries LAG, Melbert D, Krapcho M, et al., editors. Bethesda, MD: National Cancer Institute; 2008. SEER Cancer Statistics Review, 1975-2005. http://seer.cancer.gov/csr/1975_2005.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical